secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2026-07-27T20:01:09+00:00
Accession:  0001728117-26-000064
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio to submit NDA for seralutinib in PAH in Sep 2026; reacquires worldwide rights from Chiesi
--------------------------------------------------------------------------------

- FDA Pre-NDA meeting minutes allow NDA submission based on Phase 3 PROSERA plus confirmatory evidence; submission planned for September 2026.
- Gossamer reacquired worldwide rights to seralutinib from Chiesi; Chiesi pays $5M to Gossamer, no upfront cash from Gossamer; Gossamer retains majority of global economics.
- Preliminary cash, cash equivalents and marketable securities ~$57M as of June 30, 2026.
- Stockholders approved convertible note exchange (reduced debt by ~$115.9M) and authorized reverse stock split to support Nasdaq compliance.
- If NDA accepted, FDA approval decision possible in Q3 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000064/0001728117-26-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000064/goss-20260723.htm
  HTML page:      https://secwatch.observer/filing/0001728117-26-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer